Motif Bio plc (LON:MTFB)‘s stock had its “buy” rating restated by equities research analysts at Peel Hunt in a research note issued to investors on Wednesday. They presently have a GBX 106 ($1.39) price target on the stock. Peel Hunt’s price objective would indicate a potential upside of 207.25% from the stock’s previous close.

A number of other research firms have also weighed in on MTFB. Northland Securities reaffirmed a “buy” rating on shares of Motif Bio plc in a research report on Thursday, October 5th. FinnCap reaffirmed a “buy” rating and set a GBX 100 ($1.32) price objective on shares of Motif Bio plc in a research report on Wednesday, October 4th. Finally, Beaufort Securities reaffirmed a “speculative buy” rating and set a GBX 110 ($1.45) price objective on shares of Motif Bio plc in a research report on Monday, October 2nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of GBX 101.50 ($1.33).

Motif Bio plc (LON:MTFB) traded up GBX 0.25 ($0.00) during mid-day trading on Wednesday, reaching GBX 34.50 ($0.45). The company had a trading volume of 1,844,056 shares, compared to its average volume of 1,130,000. Motif Bio plc has a one year low of GBX 21.44 ($0.28) and a one year high of GBX 51.75 ($0.68).

WARNING: “Peel Hunt Reaffirms “Buy” Rating for Motif Bio plc (MTFB)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at

Motif Bio plc Company Profile

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Analyst Recommendations for Motif Bio plc (LON:MTFB)

Receive News & Ratings for Motif Bio plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio plc and related companies with's FREE daily email newsletter.